Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sumanirole vs Placebo or Ropinirole in Early Parkinson's Disease
NCT00036218Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2001
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of sumanirole in Parkinson's disease (PD) (3 arms), sponsored by Pfizer. Primary endpoint: Unified Parkinson's Disease Rating Scale Parts II and III at 26 weeks. Started Dec 2001; status: completed.
02
Drugs
sumanirole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00036218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036218.